Roxadustat is an orally active hypoxia-inducible factor (HIF) prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin.IC50 & Target:Hypoxia-inducible factor prolyl-hydroxylaseIn Vitro:Roxadustat (5-50 μM; 6 hours) significantly inhibits TBHP-induced apoptosis in PC12 cells[2].
Roxadustat (50 μM; 6 hours) stabilizes HIF-1α protein expression in PC12 cells[2].In Vivo:Roxadustat (50 mg/kg; i.p.; daily for 7 days) protects the survival of motor neurons and improves recovery from spinal cord injury[2].